Treatment with MLN4924 led to increased Cdc25A levels, whereas the levels of Wee1, another CRL target and a negative CDK1 regulator, did not consistently change in CLL cells in the presence of MLN4924 (Figure 2a). Here, CDK1 is linked to B-cell chronic lymphocytic leukemia.